Safe provision of systemic anti-cancer treatment for urological cancer patients during COVID-19: a tertiary centre experience in the first wave of COVID-19

Table 3 Patient demographics

	2019 (n = 518)		2020 (n = 441)		(n₂₀₂₀–n₂₀₁₉)/n₂₀₁₉ (%)	p value
	n	%	n	%	(n₂₀₂₀–n₂₀₁₉)/n₂₀₁₉ (%)	p value
Sex
Male	467	90.15	402	91.16	13.92	0.596
Female	51	9.85	39	8.84	23.53	0.596
Age
< 50	26	5.02	24	5.44	7.69	0.769
50–59	62	11.97	49	11.11	20.97	0.679
60–69	164	31.66	152	34.47	7.32	0.357
70–79	178	34.36	139	31.52	21.91	0.351
≥ 80	88	16.99	77	17.46	12.50	0.847
Mean (SD)—years	68.8 (11.5)	–	68.6 (11.3)	–	–
Socioeconomic status (IMD)
Low	168	32.43	145	32.88	13.69	0.883
Middle	170	32.82	143	32.43	15.88	0.897
High	178	34.36	152	34.47	14.61	0.973
Missing	2	0.39	1	0.23	50.00	0.660
Ethnicity
White British	239	46.14	190	43.08	20.50	0.343
White Other	26	5.02	28	6.35	− 7.69	0.373
Black Caribbean	36	6.95	21	4.76	41.67	0.153
Black African	17	3.28	19	4.31	− 11.76	0.405
Black Other	4	0.77	5	1.13	− 25.00	0.563
Asian	13	2.51	7	1.59	46.15	0.319
Mixed	1	0.19	0	0.00	100.00	0.356
Other	8	1.54	7	1.59	12.50	0.957
Unknown	174	33.59	164	37.19	5.75	0.245
Performance status (ECOG)
0	138	26.64	102	23.13	26.09	0.194
1	323	62.36	204	46.26	36.84	< 0.0001*
2	49	9.46	16	3.63	67.35	< 0.001*
3	8	1.54	2	0.45	75.00	0.0357
Missing	0	0.00	117	26.53	N.A	< 0.0001*

*Statistically significant p values after Bonferroni correction for multiple comparisons

ISSN: 1471-2490